Skip to main content

Advertisement

Table 2 Comparison of the prevalence of MTP joint and foot specific US detectable and clinically detectable pathology of the study participants at baseline and twelve weeks by frequency (N)

From: Improvement in symptoms and signs in the forefoot of patients with rheumatoid arthritis treated with anti-TNF therapy

Variable   Baseline 12 weeks Statistical Values
MTP joint synovial hypertrophy (US) R2 58.1% (18) 45.2% (14) p = 1.000
  R5 74.2% (23) 51.6% (16) p = 0.344
  L2 61.3% (19) 35.5% (11) p = 0.267
  L5 67.7% (21) 54.8% (17) p = 0.754
MTP joint synovitis (Doppler US) R2 6.5% (2) 6.5% (2) p = 1.000
  R5 9.7% (3) 3.2% (1) p = 0.625
  L2 3.2% (1) 0% (0) p = 1.000
  L5 9.7% (3) 6.5% (2) p = 1.000
MTP joint erosion (US) R2 25.8% (8) 25.8% (8) p = 0.250
  R5 74.2% (23) 51.6% (16) p = 0.727
  L2 9.7% (3) 12.9% (4) p = 1.000
  L5 61.3% (19) 58.1% (18) p = 1.000
Plantar forefoot bursal hypertrophy (US) R 83.9% (26) 67.7% (21) p = 1.000
  L 80.6% (25) 69.2% (18) p = 0.508
Clinically detectable plantar forefoot bursae R 41.9% (13) 32.3% (10) p = 0.012
  L 35.5% (11) 19.4% (6) p = 0.453
Clinically detectable MTP joint synovitis R 45.2% (14) 25.8% (8) p = 0.375
  L 25.8% (8) 16.1% (5) p = 0.070
  1. Key: R = Right; L = Left; 2 = second MTP joint; 5 = fifth MTP joint